643 Amniotic Membrane And Amniotic Fluid Prn
BCBS Massachusetts policy #643 addresses medical necessity coverage criteria, applicable settings, and coding for human amniotic membrane (HAM) products and related amniotic-derived products for commercial and Medicare members; it defines covered ophthalmic indications and diabetic lower-extremity ulcer use, lists covered and investigational HCPCS/CPT codes and required ICD-10 diagnoses, and prior authorization rules for inpatient care.
NuShield added to medically necessary policy statement for nonhealing diabetic lower-extremity ulcers based on RCT evidence (policy update 9/2025).
AmnioExcel added to medically necessary products for diabetic lower-extremity ulcers. Effective 1/1/2025.
Annual policy review with literature update through February 21, 2025; references added.
New investigational indication for treatment following Mohs microsurgery added in 7/2022.
Multiple historical actions clarifying coding information across many dates (1/2026, 4/2026, 10/2025, etc.).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.